A German Biotech's Seed Round Could Change How We Treat Heart Disease

Jan de Vries · 2026-08-28

Let's talk about a new player that just entered the biotech arena with a clear mission and some serious backing. Revier Therapeutics, based in Heidelberg, Germany, is officially out of stealth mode. They're focused on a huge, unmet need: cardiometabolic diseases. And they've just secured a $6.5 million Seed round to make it happen. That's right, we're talking about a fresh injection of capital to tackle conditions affecting millions. It's a significant vote of confidence in their science. ### The Backing Behind the Science So, who's betting on this early-stage vision? The funding round was led by the KHAN Technology Transfer Fund II. They didn't go it alone, though. They were joined by High-Tech Gründerfonds (HTGF), VORNvc, and a group of private investors organized through Revier Invest Heidelberg. It's a coalition that blends deep-tech venture capital with regional stakeholders. That kind of support network is often a strong signal for a startup's potential traction. ### The Problem They're Solving Here's the core issue. Prof. Eva van Rooij, PhD, the company's co-founder and CEO, puts it bluntly. She says, "Despite significant progress in cardiovascular medicine, millions of patients... still face limited targeted treatment options." She's talking about specific conditions like HFpEF (heart failure with preserved ejection fraction) and ASCVD (atherosclerotic cardiovascular disease). The current treatments often manage symptoms. Revier wants to modify the disease itself. That's a fundamental shift. Their big idea? They're going after a specific biological target: class IIa histone deacetylases, or HDACs. Think of HDACs as enzymes that play a role in how genes are expressed. When they're out of whack, they can drive disease. ### A More Precise Approach Here’s where it gets interesting. Earlier attempts to target HDACs were a bit like using a sledgehammer. They broadly inhibited multiple classes, which led to nasty side effects that limited how much medicine a patient could take. Revier's approach is designed to be a scalpel. Their orally available small molecules aim to selectively inhibit only the class IIa HDACs involved in the disease process. Prof. Johannes Backs, MD, the scientific founder, explains the advantage. He says their compounds are designed to "specifically inhibit the disease-driving enzymatic activity while preserving the essential functions." The goal is a therapy that's both effective and has a safer profile. That's the holy grail in drug development. ### What's Next for the Funding? With $6.5 million in the bank, what's the plan? The capital is earmarked for pushing their preclinical pipeline forward. Their lead program targets HFpEF, with a second program focused on ASCVD. The money will also help them build out the team. We're talking about expanding their operational, scientific, and clinical functions. They're moving from a pure research phase toward clinical trials. Michael Hamacher, PhD, from KHAN, summed up the investor enthusiasm. He highlighted Revier's "differentiated strategy" and its potential to "reshape the standard of care" by providing durable benefits for patients. It's a story we'll be watching. A German biotech, with a precise scientific approach, tackling some of the most prevalent chronic diseases on the planet. Their journey from this seed round to the clinic is just beginning.